Red Blood Cell Factory (RBC-Factory)
ID: DARPA-PS-25-08Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA)DEF ADVANCED RESEARCH PROJECTS AGCYARLINGTON, VA, 222032114, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

NATIONAL DEFENSE R&D SERVICES; DEPARTMENT OF DEFENSE - MILITARY; APPLIED RESEARCH (AC12)
Timeline
    Description

    The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals for the Red Blood Cell Factory (RBC-Factory) program, aimed at developing a medical device platform to enhance human red blood cells (RBCs) by inserting biologically active components. The primary objective is to create modified red blood cells (mRBCs) that can provide additional protections for warfighters operating in extreme environments, while also assessing the ethical, legal, and social implications (ELSI) of this technology. This initiative is critical for advancing military medical capabilities and ensuring the operational effectiveness of personnel in challenging conditions. DARPA has allocated approximately $18.1 million for this program, with proposals due by the specified deadlines, and interested parties can contact the BAA Coordinator at RBC-Factory@darpa.mil for further information.

    Point(s) of Contact
    BAA Coordinator
    RBC-Factory@darpa.mil
    Files
    Title
    Posted
    The Defense Advanced Research Projects Agency (DARPA) has issued a program solicitation for the Red Blood Cell Factory (RBC-Factory) aimed at developing a medical device platform to insert biologically active components into human red blood cells (RBCs). The initiative seeks to enhance the operational performance of warfighters in extreme environments by utilizing modified red blood cells (mRBCs) as carriers for medical countermeasures. With a budget of approximately $18.1 million, DARPA anticipates multiple awards through Other Transaction for Prototype agreements. Proposals must address several scientific questions regarding the efficiency of cargo insertion, the physiological impacts on RBCs, and the development of a scalable device for cargo integration. The program will last 21 months, requiring detailed milestones and deliverables related to device creation and scientific inquiry into mRBC properties. Proposers are encouraged to address potential ethical, legal, and social implications (ELSI) associated with the technology. They must submit an 8-page abstract followed by an invitation-only oral presentation. The solicitation emphasizes innovative, non-genetic methods and excludes genetic modifications or specific drug delivery systems. The RBC-Factory program aligns with DARPA’s mission to make strategic technology investments critical to U.S. national security.
    The document outlines the proposal for the Red Blood Cell Factory (RBC-Factory) project, emphasizing a novel technical approach to addressing the capabilities and challenges related to the production and functionality of red blood cells. Key areas of focus include the chemical and physical properties of cargo, their impact on cell function, and the scalability of processing methods. The proposal details potential risks and challenges, accompanied by strategies for their mitigation. A rough order of magnitude (ROM) cost estimate is included, outlining labor costs, materials, and other direct costs (ODCs) alongside the proposed period of performance. The document highlights the expertise of the team members and partners involved, detailing their relevance to the RBCF goals. It underscores the importance of comprehensive impact assessments while maintaining competition-sensitive information per government requirements. Overall, the proposal aims to advance the field of red blood cell production through innovative methodologies and collaborative expertise.
    The document outlines the submission requirements for proposals related to the DARPA Red Blood Cell-Factory (RBC-F) program. This competitive solicitation mandates that abstracts adhere to a specific format, including a maximum of 8 pages, and cover a technical overview, experimental plan, design of experiments, plans for meeting performance metrics, detailed milestones, risk assessments and mitigations, ethical, legal, and social implications (ELSI), and tech challenges and abilities. Proposals must contain an executive summary, approach, technology challenges, technical abilities, estimated costs not exceeding $10 million, and a comprehensive reference list. The document emphasizes clear understanding and originality in the presentation of ideas while outlining the importance of showcasing the proposer’s unique capabilities and risk management strategies. The RBC Factory's goals focus on advancements in blood cell manufacturing, redirecting potential bottlenecks in traditional production methods. It highlights the importance of structured and detailed proposals in achieving program objectives while ensuring compliance with specified formatting and content guidelines.
    The document outlines an agreement between the Defense Advanced Research Projects Agency (DARPA) and a performing entity for a research and development contract under 10 U.S.C. § 4022. It details the proposal submission process, including the opportunity for proposers to suggest edits to the model Other Transaction agreement without affecting the evaluation criteria. Key sections include the scope of the agreement, financial obligations, project management requirements, and dispute resolution procedures. It emphasizes the importance of patent rights, data rights, and safeguarding sensitive information related to defense technologies. Additionally, the agreement outlines conditions regarding foreign access to technology, cybersecurity measures, and the prohibition of telecommunications services from specified Chinese companies, ensuring national security interests are upheld. The structure is clearly divided into articles covering relevant topics, with specific attachments detailing requirements and certification processes. Overall, the agreement aims to facilitate the development of critical military technologies while ensuring compliance with federal regulations and security protocols.
    The document serves as a set of instructions for completing a Cost Proposal spreadsheet template utilized by organizations responding to government RFPs. It specifies mandatory tabs that must be completed, including the TOTAL and Budget by Milestone sections. Proposals should include detailed justifications for costs across multiple categories such as Direct Labor, Fringe Benefits, Subcontractor expenses, and other Direct Costs. Guidelines emphasize preserving existing formulas in the spreadsheet, enhancing user-friendliness by utilizing the Excel Hide function for clarity and organization. The template also outlines areas for providing detailed information about labor categories, consultants, materials, equipment, travel, and overhead costs, ultimately culminating in a total estimated cost. The aim is to create a comprehensive, transparent cost proposal that adequately supports request documentation for funding or contract awards from federal and state agencies. This effort underscores adherence to stringent cost proposal requirements essential for the approval process, ensuring all claims for financial support are well-supported and justified. The document reflects the necessary structure and rigor involved in government procurement processes.
    The document pertains to a government request for proposals (RFP) regarding the development of milestones and payment schedules for a project involving modified red blood cells (mRBCs). It outlines a spreadsheet template to be completed by proposers, indicating various milestones along with their associated deliverables and due dates, labeled as "ACA" (after contract award). Key deliverables include several impact assessments and reports relating to integration plans, technical progress, and impact on various populations. The document stresses the completion of specific tasks within designated timelines, with directions to propose additional milestones as necessary. Overall, it emphasizes collaboration between technical and assessment teams while adhering to a structured framework for evaluation and reporting throughout the project lifecycle.
    Lifecycle
    Title
    Type
    Solicitation
    Similar Opportunities
    RBC-Factory Industry Day
    Active
    Dept Of Defense
    The Defense Advanced Research Projects Agency (DARPA) is hosting a virtual Industry Day for the Red Blood Cell Factory (RBC-Factory) program, aimed at enhancing human red blood cells with biologically active components to improve warfighter performance in extreme environments. This event will provide potential proposers with insights into the program's vision, operational mechanics, and opportunities for collaboration, with a focus on innovative proposals that modify red blood cells at scale, explicitly excluding genetic modifications. The Industry Day is scheduled for January 7, 2025, with registration required by January 2, 2025, and is limited to 350 participants on a first-come, first-served basis. Interested parties can direct inquiries to Dr. Christopher Bettinger at RBC-Factory@darpa.mil, and are encouraged to submit a one-page teaming profile detailing their competencies and desired collaborations.
    Biological Technologies
    Active
    Dept Of Defense
    The Defense Advanced Research Projects Agency (DARPA) is soliciting proposals for innovative research and development in Biological Technologies under the Broad Agency Announcement (BAA) HR001124S0034. This initiative aims to explore revolutionary ideas not currently addressed by existing programs, focusing on areas such as machine learning, human performance, materials technology, and biosecurity, all intended to enhance national security. Proposals will be evaluated based on scientific merit, relevance to DARPA's mission, and cost realism, with submissions accepted on a rolling basis until September 10, 2025. Interested parties can contact the BAA Coordinator at BTOBAA2024@darpa.mil for further information.
    Cell Salvage RFI
    Active
    Dept Of Defense
    The Department of Defense, specifically the Air Force Medical Service, is seeking information from qualified companies regarding the provision of a portable cell salvage device designed to efficiently recover and condition blood for on-demand transfusions in military settings. This initiative aims to address the critical need for transportable blood supplies to treat combat-related hemorrhagic shock and significant blood loss, enhancing patient outcomes in austere environments. Interested respondents are required to provide details about their capabilities, including company background and existing products, while adhering to specific requirements such as FDA approval, military ruggedization standards, and operational efficiency. Responses must be submitted to Aaron Nelson at usaf.detrick.afmra.mbx.sg5t-market@health.mil by the specified deadline, with further details outlined in the RFI documents.
    Request for Project Information: “Single Blood Donor Collection and Storage Bags Manufactured in Continental United States (CONUS)”
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA) and the U.S. Army Medical Research and Development Command (USAMRDC), is seeking information on the manufacturing capabilities for single blood donor collection and storage bags produced within the contiguous United States. This Request for Project Information (RPI) aims to address critical shortages of blood storage bags necessary for military operations, particularly in trauma situations where timely access to blood products can be life-saving. Interested parties are invited to submit Project Information Papers detailing their compliance with regulatory standards, manufacturing capabilities, and plans to produce a prototype system within two years, with submissions due by January 6, 2025. For further inquiries, contact Dr. Chuck Hutti at chuck.hutti@ati.org or Mr. Evan Kellinger at mtec-sc@ati.org.
    Disruptioneering Program Announcement
    Active
    Dept Of Defense
    The Defense Advanced Research Projects Agency (DARPA) is announcing the Disruptioneering Program, inviting proposals for high-risk, high-reward research initiatives aimed at advancing national security applications. This program seeks to rapidly investigate new technologies through targeted Disruption Opportunities (DOs), enabling the development of innovative prototypes within a streamlined timeframe of less than 120 days from idea inception. Proposals must be unclassified and adhere to specific submission formats, with funding awards anticipated to reach up to $2 million, requiring a minimum one-third cost share. Interested parties can contact the BAA Coordinator at DARPA-PA-24-04@darpa.mil for further details and guidance on proposal submissions.
    Hematology CPRR - Keesler AFB, MS
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting proposals for a hematology system to be delivered to the Keesler Medical Center at Keesler Air Force Base in Mississippi. The procurement requires one hematology system that includes two functioning analyzers, a slide maker stainer, and a digital cell morphology system equipped with advanced software for red blood cell morphology. This system is crucial for enhancing patient care and operational capabilities within military healthcare, as it will facilitate the processing of 31,000 complete blood counts over a five-year period. Interested vendors must ensure that their equipment is FDA-approved, meets specific technical specifications, and complies with cybersecurity standards as outlined in the Medical Device and Equipment Risk Assessment. The deadline for proposals has been extended to January 24, 2025, with the period of performance beginning on April 1, 2025. For further inquiries, interested parties can contact Carolynn Benn at carolynn.j.benn.civ@health.mil or David Erpelding at david.k.erpelding.civ@health.mil.
    2025 CB Warfighter Engagements
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Threat Reduction Agency (DTRA), is seeking innovative technologies for the 2025 CB Warfighter Engagements aimed at enhancing capabilities in chemical, biological, and radiological (CBR) defense. This Request for Information (RFI) invites participation from industry and academia to develop technologies that will assist Warfighters in understanding, protecting against, and mitigating CBR threats, with a focus on three key events scheduled for April and June 2025. The initiative emphasizes the importance of rugged prototypes for hands-on evaluation and aims to foster collaboration between technology developers and military users to optimize defense readiness in contested environments. Interested parties should submit their proposals by December 30, 2024, and can direct inquiries to DTRA RD-CBW Submissions at dtra.belvoir.rd.mbx.rd-cbw-submissions@mail.mil.
    Advanced Robotics and Automation for Manufacturing & Sustainment (ARAMS}
    Active
    Dept Of Defense
    The Department of Defense, specifically the Air Force Research Laboratory (AFRL), is seeking proposals for the Advanced Robotics and Automation for Manufacturing & Sustainment (ARAMS) initiative. This effort aims to establish a consortium of organizations to conduct research, development, testing, and evaluation (RDT&E) of dual-use robotics and automation technologies that enhance manufacturing and sustainment capabilities for the Air Force. The program is critical for addressing capability gaps in defense production and improving efficiency, with a total projected budget of $87.7 million available for innovative proposals due by January 6, 2025. Interested parties can contact Michael Corbett at 937-623-9474 or via email at Michael.corbett.13@us.af.mil for further information.
    DLA Emergent IV Research and Development Program
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is seeking innovative research and development solutions through the Emergent IV Research and Development Program, designated as BAA0001-22. This Broad Agency Announcement (BAA) aims to address unanticipated needs in various areas of interest, including advanced manufacturing, medical logistics, and artificial intelligence applications, with a funding ceiling of $125 million over a five-year period. The program emphasizes the importance of fostering technological advancements to enhance operational efficiency and effectiveness within the DLA's logistics and supply chain processes. Interested parties are encouraged to submit initial White Papers summarizing their proposals, with key deadlines for submissions and notifications outlined in the amendments. For further inquiries, potential contractors can contact the DLA at RandD.DCSO@dla.mil or Sara Lobley at sara.lobley@dla.mil.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research Department of Defense Dept. of the Army -- USAMRAA
    Active
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE DEPT OF THE ARMY is seeking extramural research and development ideas for medical research. The USAMRDC aims to provide solutions to medical problems for the American Service Member and the general public. This BAA solicits basic and applied research projects to advance medical science and technology. The selection process is highly competitive, and submissions are accepted throughout a 5-year period. Pre-proposals must be submitted through the electronic Biomedical Research Application Portal (eBRAP), and invited full proposals must be submitted through Grants.gov.